LYCA · Insider Trading
Lycia Therapeutics, Inc. Common Stock
Every open-market purchase and sale reported by LYCA officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-30 | Venrock Healthcare Capital Partners XP, L.P. | 10%+ Owner | Buy | +225,036 | +$5.80M |
| 2026-10-28 | Versant Vantage II GP-GP, LLC | 10%+ Owner | C | +42,151,842 | — |
| 2026-10-27 | Venrock Healthcare Capital Partners III, L.P. | 10%+ Owner | MIXED | +61,427,097 | +$338.88M |
| 2026-10-26 | Amy Bachrodt | Chief Financial Officer | A | +399,746 deriv. | — |
| 2026-10-26 | Steven Staben | Chief Scientific Officer | A | +110,896 deriv. | — |
| 2026-10-26 | Sofia Touami | Chief Business Officer | A | +68,755 deriv. | — |
| 2026-10-26 | Chin Hyok Lee | Chief Medical Officer | A | +73,191 deriv. | — |
| 2026-10-26 | Laurent Fischer | Director | A | +33,307 deriv. | — |
| 2026-10-26 | William Jl Rieflin | Director | A | +44,840 deriv. | — |
| 2026-10-26 | Jane Henderson | Director | A | +77,666 deriv. | — |
| 2026-10-26 | Aetna Wun Trombley | President and CEO | A | +443,586 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Venrock Healthcare Capital Partners XP, L.P. | 10%+ Owner | 6,850,237 | — |
| Venrock Healthcare Capital Partners III, L.P. | 10%+ Owner | 6,785,437 | — |
| Versant Vantage II GP-GP, LLC | 10%+ Owner | 5,631,425 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the LYCA quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.